Trino Therapeutics
Dublin
About Trino Therapeutics
Trino is a drug discovery and early drug development company focused on anti-inflammatory therapeutics. The company is developing drug candidates from a novel, proprietary, class of drugs based on indane dimers derived from a Taiwanese fern. Its lead candidate is a potential first-in-class drug for the treatment of inflammatory bowel disease (IBD), which could be used in both ulcerative colitis (UC) and Crohn’s disease (CD). Trino’s drug class also offers promising candidates with a broad anti-inflammatory activity that could be suitable for applications in dermatology, pulmonary and auto-immune disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $11.6M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2013)
- Website: trinotherapeutics.com
- Phone: +353 1 670 9865
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/trino-therapeutics-2757406 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.